Outlook Therapeutics (NASDAQ:OTLK – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report ...
Iris Energy (NASDAQ:IREN – Free Report) had its price objective boosted by HC Wainwright from $13.00 to $16.00 in a research ...
Fintel on MSN4d
HC Wainwright & Co. Downgrades Poseida Therapeutics (PSTX)Fintel reports that on November 26, 2024, HC Wainwright & Co. downgraded their outlook for Poseida Therapeutics ...
Fintel on MSN5d
HC Wainwright & Co. Downgrades Mainz Biomed N.V. (MYNZ)Fintel reports that on November 25, 2024, HC Wainwright & Co. downgraded their outlook for Mainz Biomed N.V. (NasdaqCM:MYNZ) ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (LSE:0L35) with a Sell recommendation. As of November 21, 2024, the average one-year price ...
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a ...
HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm primarily focusing on neurological and neuropsychiatry disorders.
Fintel reports that on November 25, 2024, HC Wainwright & Co. initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sell recommendation. As of November 21, 2024, the average one-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback